Claims for Patent: 10,004,788

Summary for Patent: 10,004,788

Title:	Treatment of ocular neovascularization using anti-VEGF proteins
Abstract:	The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
Inventor(s):	Constable; Ian J. (Mosman Park, AU), Rakoczy; P. Elizabeth (Scarborough, AU), Lai; Chooi-May (Waterford, AU), Chalberg, Jr.; Thomas W. (Redwood City, CA)
Assignee:	Avalanche Australia Pty Ltd. (Southbank, AU)
Application Number:	15/851,650
Patent Claims:	1. A method for the treatment of ocular neovascularization in an eye of a human subject suffering from ocular neovascularization, said eye of the human subject having previously received a first intravitreal injection of an anti-Vascular Endothelial Growth Factor (VEGF) agent in an amount such that the anti-VEGF agent is present in the eye of the subject at a concentration sufficient to prevent progression of the neovascularization at the time of application of the method, the method comprising: administering to the eye of the human subject a single unit dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant virus comprising a nucleic acid sequence encoding an anti-VEGF protein, wherein the single unit dose comprises at least 1.times.10.sup.6 and at most 1.times.10.sup.15 vector genomes of the recombinant virus, and is sufficient to cause elevated levels of said anti-VEGF protein in the eye of said human subject when measured at least one year after the administration of the pharmaceutical composition; wherein the eye of the subject does not require rescue treatment with an anti-VEGF agent to arrest or reverse progression of the ocular neovascularization during the period between about 180 days and about one year following the administration of the pharmaceutical composition. 2. The method of claim 1 wherein the recombinant virus is a recombinant adeno-associated virus (rAAV). 3. The method of claim 2, wherein the rAAV is selected from the group consisting of: AAV1, AAV2, AAV2.5 AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. 4. The method of claim 3, wherein the rAAV is selected from the group consisting of: AAV2 and AAV8. 5. The method of claim 2, wherein the single unit dose comprises at least 1.times.10.sup.9 and at most 3.times.10.sup.13 vector genomes of the rAAV. 6. The method of claim 2, wherein the eye of the subject has received the first intravitreal injection of an anti-VEGF agent between about 1 to 30 days prior to the administration of the pharmaceutical composition. 7. The method of claim 2, wherein the anti-VEGF agent is aflibercept. 8. The method of claim 2, wherein the anti-VEGF agent is ranibizumab. 9. The method of claim 2, wherein the anti-VEGF protein is aflibercept. 10. The method of claim 2, wherein the eye of the subject does not require rescue treatment with an anti-VEGF agent to arrest or reverse progression of the ocular neovascularization during the period between about 90 days and about one year following the administration of the pharmaceutical composition. 11. The method of claim 2, further comprising measuring visual acuity in the eye of the subject by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after the administering of the pharmaceutical composition, wherein the best corrected visual acuity (BCVA) of the human subject improves by at least 1 line as measured by ETDRS letters following the administering of the pharmaceutical composition. 12. A method for the treatment of subfoveal choroidal neovascularization (CNV) in the eye of a human subject suffering from subfoveal CNV secondary to wet age-related macular degeneration, said eye of the human subject having previously received one or more intravitreal injections of an anti-VEGF agent within about 30 days, the method comprising: administering to the eye of the human subject a single unit dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an rAAV comprising a nucleic acid sequence encoding an anti-VEGF protein, wherein the single unit dose comprises at least 1.times.10.sup.6 and at most 1.times.10.sup.15 vector genomes of the rAAV, and is sufficient to reduce the subfoveal CNV in the subject for at least one year after the administration of the pharmaceutical composition, wherein the subject does not require rescue treatment with an anti-VEGF agent to arrest or reverse progression of the subfoveal CNV during the period between about 180 days and about one year following the administration of the pharmaceutical composition. 13. The method of claim 12, wherein the rAAV is selected from the group consisting of: AAV1, AAV2, AAV2.5 AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. 14. The method of claim 13, wherein the rAAV is selected from the group consisting of: AAV2 and AAV8. 15. The method of claim 12, wherein the single unit dose comprises at least 1.times.10.sup.9 and at most 3.times.10.sup.13 vector genomes of the rAAV. 16. The method of claim 12, wherein the anti-VEGF agent is aflibercept. 17. The method of claim 12, wherein the anti-VEGF agent is ranibizumab. 18. The method of claim 12, wherein the anti-VEGF protein is aflibercept. 19. The method of claim 12, wherein the eye of the subject does not require rescue treatment with an anti-VEGF agent to arrest or reverse progression of the ocular neovascularization during the period between about 90 days and about one year following the administration of the pharmaceutical composition. 20. The method of claim 12, further comprising measuring visual acuity in the eye of the subject by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after the administering of the pharmaceutical composition, wherein the best corrected visual acuity (BCVA) of the human subject improves by at least 1 line as measured by ETDRS letters following the administering of the pharmaceutical composition. 21. A method for the treatment of ocular neovascularization in an eye of a human subject having ocular neovascularization secondary to wet-AMD, said eye of the human subject having received a first intravitreal injection of an anti-VEGF agent within about 1 to 30 days prior to application of the method, the method comprising: administering to the eye of the human subject a single unit dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an rAAV comprising a nucleic acid sequence encoding an anti-VEGF protein, wherein the rAAV is selected from the group consisting of AAV2 and AAV8, wherein the single unit dose is administered via sub-retinal injection, and comprises at least 1.times.10.sup.9 and at most 3.times.10.sup.13 vector genomes of the rAAV, and is sufficient to reduce the ocular neovascularization in the eye of the subject for at least one year after the administration of the pharmaceutical composition, and wherein the eye of the subject does not require rescue treatment with an anti-VEGF agent to arrest or reverse progression of the ocular neovascularization during the period between about 180 days and about one year following the administration of the pharmaceutical composition. 22. The method of claim 21, wherein the anti-VEGF agent is ranibizumab. 23. The method of claim 21, wherein the eye of the subject does not require rescue treatment with an anti-VEGF agent to arrest or reverse progression of the ocular neovascularization during the period between about 90 days and about one year following the administration of the pharmaceutical composition. 24. A method for the treatment of ocular neovascularization in an eye of a human subject having ocular neovascularization secondary to wet-AMD, wherein the eye of the subject has received a first intravitreal injection of an anti-VEGF agent between about 1 to 30 days prior to initiation of the method, the method comprising: administering to the eye of the human subject a single unit dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an rAAV comprising a nucleic acid sequence encoding aflibercept, wherein the single unit dose is administered via intravitreal injection, and comprises at least 1.times.10.sup.9 and at most 3.times.10.sup.13 vector genomes of the rAAV and is sufficient to reduce the ocular neovascularization in the eye of the subject for at least one year after the administration of the pharmaceutical composition, wherein the subject does not require rescue treatment with an anti-VEGF agent to arrest or reverse progression of the ocular neovascularization during the period between about 180 days and about one year following the administration of the pharmaceutical composition. 25. The method of claim 24 wherein the anti-VEGF agent is aflibercept. 26. The method of claim 25, wherein the eye of the human subject has received sufficient aflibercept prior to initiation of the method so that progression of the ocular neovascularization at the time of administration of the pharmaceutical composition has been halted. 27. The method of claim 24, wherein the eye of the subject does not require rescue treatment with an anti-VEGF agent to arrest or reverse progression of the ocular neovascularization during the period between about 90 days and about one year following the administration of the pharmaceutical composition.

Details for Patent 10,004,788

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006	10,004,788	2032-05-15
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012	10,004,788	2032-05-15
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	October 13, 2016	10,004,788	2032-05-15
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	March 20, 2018	10,004,788	2032-05-15